Interleukin‐1β influences the effect of infliximab on temporomandibular joint pain in rheumatoid arthritis

References

• Tegelberg A., Kopp S. Clinical findings in the stomatognathic system for individuals with rheumatoid arthritis and osteoarthrosis. Acta Odontol Scand 1987; 45: 65–75
   PubMed Web of Science ®Google Scholar
• Helenius L. M. J., Hallikainen D., Helenius I., Meurman J. H., Koskimies S., Tervahartiala P., et al. HLA‐DRB1* alleles and temporomandibular joint erosion in patients with various rheumatic diseases. Scand J Rheumatol 2004; 33: 24–9
   PubMed Web of Science ®Google Scholar
• Dinarello C. A. Interleukin‐1, interleukin‐1 receptors and interleukin‐1 receptor antagonist. Int Rev Immunol 1998; 16: 457–99
   PubMedGoogle Scholar
• Niedel J., Schulze M., Lindshau J. Association between degree of bone‐erosion and synovial fluid‐levels of tumor necrosis factor alpha in the knee‐joints of patients with rheumatoid arthritis. Inflamm Res 1995; 44: 217–21
   PubMed Web of Science ®Google Scholar
• Rosengren S., Firestein G. S., Boyle D. L. Measurement of inflammatory biomarkers in synovial tissue extracts by enzyme‐linked immunosorbent assay. Clin Diagn Lab Immunol 2003; 10: 1002–10
   PubMedGoogle Scholar
• Watkins L. R., Wiertelak E. P., Goehler L. E., Smith K. P., Martin D., Maier S. F. Characterization of cytokine‐induced hyperalgesia. Brain Res 1994; 654: 15–26
   PubMed Web of Science ®Google Scholar
• van de Loo A. A., Arntz O. J., Bakker A. C., van Lent P. L., Jacobs M. J., van den Berg W. B. Role of interleukin 1 in antigen‐induced exacerbations of murine arthritis. Am J Pathol 1995; 146: 239–49
   PubMed Web of Science ®Google Scholar
• Nordahl S., Alstergren P., Kopp S. Tumor necrosis factor‐alpha in synovial fluid and plasma from patients with chronic connective tissue disease and its relation to temporomandibular joint pain. J Oral Maxillofac Surg 2000; 58: 525–30
   PubMed Web of Science ®Google Scholar
• van den Berg W. B. Anti‐cytokine therapy in chronic destructive arthritis. Arthritis Research 2001; 3: 18–26
   PubMedGoogle Scholar
• Young R. E., Thompson R. D., Nourshargh S. Divergent mechanisms of action of the inflammatory cytokines interleukin 1‐beta and tumour necrosis factor‐alpha in mouse cremasteric venules. Br J Pharmacol 2002; 137: 1237–46
   PubMed Web of Science ®Google Scholar
• Shi J., Schmitt‐Talbot E., DiMattia D. A., Dullea R. G. The differential effects of IL‐1 and TNF‐alpha on proinflammatory cytokine and matrix metalloproteinase expression in human chondrosarcoma cells. Inflamm Res 2004; 53: 377–89
   PubMed Web of Science ®Google Scholar
• Ulfgren A. K., Gröndal L., Lindblad S., Khademi M., Johnell O., Klareskog L., et al. Interindividual and intra‐articular variation of proinflammatory cytokines in patients with rheumatoid arthritis: potential implications for treatment. Ann Rheum Dis 2000; 59: 439–47
   PubMed Web of Science ®Google Scholar
• Alstergren P., Ernberg M., Kvarnström M., Kopp S. Interleukin‐1β in synovial fluid from the arthritic temporomandibular joint and its relation to pain, mobility and anterior open bite. J Oral Maxillofac Surg 1998; 56: 1059–65
   PubMed Web of Science ®Google Scholar
• Nordahl S., Alstergren P., Eliasson S., Kopp S. Interleukin‐1β in plasma and synovial fluid in relation to radiographic changes in arthritic temporomandibular joints. Eur J Oral Sci 1998; 106: 559–63
   PubMed Web of Science ®Google Scholar
• Jouvenne P., Vannier E., Dinarello C. A., Miossec P. Elevated levels of soluble interleukin‐1 receptor type II and interleukin‐1 receptor antagonist in patients with chronic arthritis: correlations with markers of inflammation and joint destruction. Arthritis Rheum 1998; 41: 1083–9
   PubMed Web of Science ®Google Scholar
• Alstergren P., Benavente C., Kopp S. Interleukin‐1beta, interleukin‐1 receptor antagonist, and interleukin‐1 soluble receptor II in temporomandibular joint synovial fluid from patients with chronic polyarthritides. J Oral Maxillofac Surg 2003; 61: 1171–8
   PubMed Web of Science ®Google Scholar
• Voog U., Alstergren P., Eliasson S., Leibur E., Kallikorm R., Kopp S. Progression of radiographic changes in the temporomandibular joints of patients with rheumatoid arthritis in relation to inflammatory markers and mediators in the blood. Acta Odontol Scand 2004; 62: 7–13
   PubMed Web of Science ®Google Scholar
• Maini R. N., Breedveld F. C., Kalden J. R., Smolen J. S., Davis D., Macfarlane J. D., et al. Therapeutic efficacy of multiple intravenous infusions of anti‐tumor necrosis factor alpha monoclonal antibody combined with low‐dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998; 41: 1552–63
   PubMed Web of Science ®Google Scholar
• Moreland L. W. Inhibitors of tumor necrosis factor for rheumatoid arthritis. J Rheumatol 1999; 26: 7–15
   PubMed Web of Science ®Google Scholar
• Hochberg M. C., Lebwohl M. G., Plevy S. E., Hobbs K. F., Yocum D. E. The benefit/risk profile of TNF‐blocking agents: findings of a consensus panel. Semin Arthritis Rheum 2005; 34: 819–36
   PubMed Web of Science ®Google Scholar
• Maini R., St Clair E. W., Breedveld F., Furst D., Kalden J., Weisman M., et al. Infliximab (chimeric anti‐tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999; 354: 1932–9
   PubMed Web of Science ®Google Scholar
• Lipsky P. E., van der Heijde D. M., St Clair E. W., Furst D. E., Breedveld F. C., Kalden J. R., et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti‐Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000; 343: 1594–602
   PubMed Web of Science ®Google Scholar
• Mugnier B., Roudier J. Factors predicting responsiveness to anti‐TNFalpha therapy in patients with rheumatoid arthritis: using biotherapies rationally. Joint Bone Spine 2004; 71: 91–4
   PubMed Web of Science ®Google Scholar
• Kopp S., Alstergren P., Ernestam S., Nordahl S., Bratt J. Reduction of temporomandibular joint pain after infliximab treatment is associated with changes in synovial fluid and plasma cytokines in rheumatoid arthritis. Cells Tissues Organs 2005; 180: 22–30
   PubMed Web of Science ®Google Scholar
• Rudwaleit M., Listing J., Brandt J., Braun J., Sieper J. Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. Ann Rheum Dis 2004; 63: 665–70
   PubMed Web of Science ®Google Scholar
• Wolbink G. J., Voskuyl A. E., Lems W. F., de Groot E., Nurmohamed M. T., Tak P. P., et al. Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis 2005; 64: 704–7
   PubMed Web of Science ®Google Scholar
• Ulfgren A. K., Andersson U., Engstrom M., Klareskog L., Maini R. N., Taylor P. C. Systemic anti‐tumor necrosis factor alpha therapy in rheumatoid arthritis down‐regulates synovial tumor necrosis factor alpha synthesis. Arthritis Rheum 2000; 43: 2391–6
   PubMed Web of Science ®Google Scholar
• Arnett F. C., Edworthy S. M., Bloch D. A., McShane D. J., Fries J. F., Cooper N. S., et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315–24
   PubMed Web of Science ®Google Scholar
• Alstergren P., Kopp S., Theodorsson E. Synovial fluid sampling from the temporomandibular joint: sample quality criteria and levels of interleukin‐1 beta and serotonin. Acta Odontol Scand 1999; 57: 16–22
   PubMed Web of Science ®Google Scholar
• Vey E., Zhang J. H., Dayer J. M. IFN‐gamma and 1,25(OH)2D3 induce on THP‐1 cells distinct patterns of cell surface antigen expression, cytokine production, and responsiveness to contact with activated T cells. J Immunol 1992; 149: 2040–6
   PubMed Web of Science ®Google Scholar
• Isler P., Vey E., Zhang J. H., Dayer J. M. Cell surface glycoproteins expressed on activated human T cells induce production of interleukin‐1 beta by monocytic cells: a possible role of CD69. Eur Cytokine Netw 1993; 4: 15–23
   PubMed Web of Science ®Google Scholar
• Lacraz S., Isler P., Vey E., Welgus H. G., Dayer J. M. Direct contact between T lymphocytes and monocytes is a major pathway for induction of metalloproteinase expression. J Biol Chem 1994; 269: 22027–33
   PubMed Web of Science ®Google Scholar
• Chizzolini C., Chicheportiche R., Burger D., Dayer J. M. Human Th1 cells preferentially induce interleukin (IL)‐1beta while Th2 cells induce IL‐1 receptor antagonist production upon cell/cell contact with monocytes. Eur J Immunol 1997; 27: 171–7
   PubMed Web of Science ®Google Scholar
• Alstergren P., Ernberg M., Kopp S., Lundeberg T., Theodorsson E. TMJ pain in relation to circulating neuropeptide Y, serotonin, and interleukin‐1 beta in rheumatoid arthritis. J Orofac Pain 1999; 13: 49–55
   PubMedGoogle Scholar
• Kopp S., Alstergren P. Blood serotonin and joint pain in seropositive versus seronegative rheumatoid arthritis. Mediators Inflamm 2002; 11: 211–17
   PubMed Web of Science ®Google Scholar
• Zeller J., Weissbarth E., Baruth B., Mielke H., Deicher H. Serotonin content of platelets in inflammatory rheumatic diseases: correlation with clinical activity. Arthritis Rheum 1983; 26: 532–40
   PubMed Web of Science ®Google Scholar
• Eastgate J. A., Symons J. A., Wood N. C., Capper S. J., Duff G. W. Plasma levels of interleukin‐1‐alpha in rheumatoid arthritis. Br J Rheumatol 1991; 30: 295–7
   PubMedGoogle Scholar
• Gutierrez S., Palacios I., Egido J., Zarco P., Miguelez R., Gonzalez E., et al. IL‐1 beta and IL‐6 stimulate the production of platelet‐activating factor (PAF) by cultured rabbit synovial cells. Clin Exp Immunol 1995; 99: 364–8
   PubMed Web of Science ®Google Scholar
• Alessandri C., Bombardieri M., Papa N., Cinquini M., Magrini L., Tincani A., et al. Decrease of anti‐cyclic citrullinated peptide antibodies and rheumatoid factor following anti‐TNFalpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement. Ann Rheum Dis 2004; 63: 1218–21
   PubMed Web of Science ®Google Scholar
• Oberg T., Carlsson G. E., Fajers C. M. The temporomandibular joint. A morphologic study on a human autopsy material. Acta Odontol Scand 1971; 29: 349–84
   PubMed Web of Science ®Google Scholar